Vertex Pharmaceuticals on Monday reported disappointing first-quarter earnings impacted by weaker-than-expected sales of its drugs for cystic fibrosis, and little or no contributions from a gene ...

Vertex Pharmaceuticals' experimental drug reduced acute, post-surgical pain without the risk of addiction, a major milestone in the company's decades-long efforts to bring a non-opioid pain ...

Vertex Pharmaceuticals (VRTX 0.59%) has built a billion-dollar cystic fibrosis (CF) treatment empire, but investors have been looking for something more. They've hoped to see the company broaden ...

O nce again, Vertex Pharmaceuticals and a U.K. government agency are at odds over the value of life-saving cystic fibrosis medicines.. In draft guidance published late last week, the National ...

Vertex is expected to post earnings of $4.24 per share for the current quarter, representing a year-over-year change of +133.1%. Over the last 30 days, the Zacks Consensus Estimate has changed -0%.

Monday, H.C. Wainwright analyst Andrew Fein increased the price target for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to $550 from the previous $535, while maintaining a Buy rating on the ...

Vertex Pharmaceuticals is not making its drug, Trikafta, available in poorer countries, where thousands of diagnosed patients stand to benefit. Shwetha Sree, left, with her 5-year-old son Vihaan ...

VX-264 and zimislecel came from Vertex’s 2019 acquisition of privately held Semma Therapeutics. The $950 million deal established Vertex’s presence in type 1 diabetes therapy R&D. In 2022 ...

Just a week after Vertex’s stem cell therapy to treat type 1 diabetes was released from an FDA clinical hold, the company is clearing out potential competition by buying ViaCyte for $320 million.

The Food and Drug Administration yesterday approved Vertex Pharmaceuticals’ latest cystic fibrosis drug, offering new hope for about 8,500 of the 30,000 Americans who suffer from the life ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to trigger sufficient levels of insulin production in a phase 1/2 trial ...